AUM: $19.1B · Form ADV, 31 Jul 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: RVMD | Current | Biological Products, (No Diagnostic Substances) | COM | 2,124,000 | -268,000 | -11.2% | 0.98% | $694M | -$6M | 10.73% | $34.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BKD | Current | Services-Nursing & Personal Care Facilities | COM | 11,637,032 | 0 | 0.0% | 4.86% | $552M | -$221M | 8.53% | $2.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: CNC | Current | Hospital & Medical Service Plans | COM | 4,901,000 | 0 | 0.0% | 0.99% | $304M | -$10M | 4.71% | $32.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| UNITED THERAPEUTICS Corp | Nasdaq: UTHR | Current | Pharmaceutical Preparations | COM | 540,598 | +83,598 | +18.3% | 1.27% | $293M | +$45M | 4.53% | $23.8B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CELC | Current | Services-Medical Laboratories | COM | 2,397,664 | +946,650 | +65.2% | 4.88% | $287M | +$22M | 4.44% | $2.8B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PRAX | Current | Pharmaceutical Preparations | COM NEW | 963,351 | 0 | 0.0% | 3.45% | $281M | -$42M | 4.34% | $8.7B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ARWR | Current | Pharmaceutical Preparations | COM | 843,063 | -545,992 | -39.3% | 0.60% | $261M | -$93M | 4.03% | $6.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| GENMAB A/S | Nasdaq: GMAB | Current | Pharmaceutical Preparations | SPONSORED ADS | 6,865,000 | 0 | 0.0% | $245M | +$56M | 3.79% | $31.7B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: VTRS | Current | Pharmaceutical Preparations | COM | 10,938,000 | -9,268,170 | -45.9% | 0.95% | $194M | -$127M | 3.00% | $22.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: COGT | Current | Pharmaceutical Preparations | COM | 5,957,000 | +950,896 | +19.0% | 3.42% | $191M | -$3M | 2.95% | $4.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IONS | Current | Pharmaceutical Preparations | COM | 2,660,669 | +681,000 | +34.4% | 1.60% | $185M | -$65M | 2.86% | $4.5B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LEGN | Current | Pharmaceutical Preparations | SPONSORED ADS | 8,137,638 | 0 | 0.0% | $162M | -$73M | 2.50% | $3.1B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Vera Therapeutics, Inc. | Nasdaq: VERA | Current | Pharmaceutical Preparations | CL A | 4,338,778 | +422,378 | +10.8% | 6.00% | $140M | -$28M | 2.17% | $1.9B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: TNGX | Current | Pharmaceutical Preparations | COM | 5,180,000 | +989,389 | +23.6% | 3.06% | $129M | -$2M | 2.00% | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BCRX | Current | Biological Products, (No Diagnostic Substances) | COM | 15,490,928 | +394,525 | +2.6% | 6.02% | $129M | -$22M | 2.00% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BMRN | Current | Pharmaceutical Preparations | COM | 2,025,146 | +692,310 | +51.9% | 1.05% | $122M | +$45M | 1.88% | $11.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LRMR | Current | Pharmaceutical Preparations | COM | 35,606,974 | 0 | 0.0% | 34.03% | $114M | +$5M | 1.76% | $337M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Newamsterdam Pharma Company | Current | ORDINARY SHARES | 4,347,101 | -10,475 | -0.2% | $105M | -$42M | 1.62% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: MLYS | Current | Pharmaceutical Preparations | COM | 3,958,000 | 0 | 0.0% | 4.47% | $99M | -$7M | 1.54% | $1.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BSX | Current | Surgical & Medical Instruments & Apparatus | COM | 2,135,440 | +820,440 | +62.4% | 0.15% | $93M | +$37M | 1.44% | $62.3B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| CHEMED CORP | NYSE: CHE | Current | Services-Home Health Care Services | COM | 182,000 | +152,000 | +506.7% | 1.40% | $92M | +$78M | 1.42% | $7.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| NYSE: INSP | Current | Surgical & Medical Instruments & Apparatus | COM | 1,296,862 | 0 | 0.0% | 4.48% | $90M | +$32M | 1.39% | $1.6B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Tempus AI, Inc. | Nasdaq: TEM | Current | Services-Computer Programming, Data Processing, Etc. | NOTE 0.750% 7/1 | New | $88M | +$88M | 1.36% | $10.9B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |||
| Nasdaq: ZBIO | Current | Pharmaceutical Preparations | NOTE 2.500% 4/0 | +6.7% | $86M | +$5M | 1.33% | $1.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| BIO-RAD LABORATORIES, INC. | NYSE: BIO | Current | Laboratory Analytical Instruments | CL A | 226,070 | 0 | 0.0% | $85M | +$19M | 1.32% | $9.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PHVS | Current | Pharmaceutical Preparations | COM | 2,590,000 | -786,042 | -23.3% | $82M | -$35M | 1.27% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Dianthus Therapeutics, Inc. /DE/ | Nasdaq: DNTH | Current | Pharmaceutical Preparations | COM | 914,000 | -211,313 | -18.8% | 1.62% | $80M | -$29M | 1.24% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IDYA | Current | Pharmaceutical Preparations | COM | 2,003,000 | -711,503 | -26.2% | 2.07% | $77M | -$24M | 1.19% | $2.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Syndax Pharmaceuticals Inc | Nasdaq: SNDX | Current | Pharmaceutical Preparations | COM | 3,779,900 | 0 | 0.0% | 4.23% | $71M | -$12M | 1.10% | $822M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Alignment Healthcare, Inc. | Nasdaq: ALHC | Current | Hospital & Medical Service Plans | COM | 1,172,418 | -31.9% | 0.56% | $71M | -$33M | 1.09% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SVRA | Current | Pharmaceutical Preparations | COM | 13,569,000 | 0 | 0.0% | 6.15% | $70M | -$14M | 1.08% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Certara, Inc. | Nasdaq: CERT | Current | Services-Prepackaged Software | COM | 7,512,928 | 0 | 0.0% | 4.93% | $69M | +$20M | 1.07% | $1.6B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ACHC | Current | Services-Specialty Outpatient Facilities, NEC | COM | 2,493,589 | -2,026,411 | -44.8% | 2.68% | $69M | -$65M | 1.06% | $3.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| AdaptHealth Corp. | Nasdaq: AHCO | Current | Services-Home Health Care Services | COMMON STOCK | 11,477,730 | 0 | 0.0% | 8.41% | $65M | -$55M | 1.00% | $990M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: PBLS | Current | Pharmaceutical Preparations | COM | 1,880,704 | 0 | 0.0% | $61M | +$9M | 0.94% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: XENE | Current | Pharmaceutical Preparations | COM | 1,615,696 | 0 | 0.0% | 1.64% | $60M | -$37M | 0.93% | $3.7B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: NVST | Current | Dental Equipment & Supplies | COM | 2,210,100 | 0 | 0.0% | 1.38% | $52M | -$6M | 0.80% | $3.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | COM | 1,823,500 | 0 | 0.0% | 2.79% | $47M | -$12M | 0.73% | $1.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: ZTS | Current | Pharmaceutical Preparations | CL A | 632,000 | +632,000 | New | 0.16% | $44M | +$44M | 0.68% | $32.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LIVN | Current | Electromedical & Electrotherapeutic Apparatus | NOTE 2.500% 3/1 | -5.4% | $44M | -$3M | 0.68% | $5.1B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: IRON | Current | Pharmaceutical Preparations | COM | 657,000 | 0 | 0.0% | 1.44% | $43M | -$5M | 0.67% | $3.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BBNX | Current | Surgical & Medical Instruments & Apparatus | COM | 1,903,710 | +579,710 | +43.8% | 3.50% | $36M | +$15M | 0.56% | $724M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GPCR | Current | Pharmaceutical Preparations | SPONSORED ADS | 1,086,000 | 0 | 0.0% | 0.51% | $34M | -$24M | 0.53% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SPRY | Current | Pharmaceutical Preparations | COM | 7,503,812 | 0 | 0.0% | 7.46% | $32M | -$28M | 0.50% | $338M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BLTE | Current | Pharmaceutical Preparations | SPONSORED ADS | 190,000 | -167,199 | -46.8% | $32M | -$23M | 0.50% | $6.1B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: COO | Current | Ophthalmic Goods | COM | 557,000 | +557,000 | New | 0.29% | $31M | +$31M | 0.49% | $11.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| BlossomHill Therapeutics, Inc. | Nasdaq: BLSM | Current | Pharmaceutical Preparations | COM | 1,446,000 | +1,446,000 | New | 4.55% | $27M | +$27M | 0.42% | $458M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Odyssey Therapeutics, Inc. | Nasdaq: ODTX | Current | Biological Products, (No Diagnostic Substances) | COMMON STOCK | 1,046,139 | 0 | 0.0% | 2.18% | $23M | +$4M | 0.36% | $882M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: TNDM | Current | Surgical & Medical Instruments & Apparatus | COM NEW | 1,390,909 | +1,390,909 | New | 1.99% | $23M | +$23M | 0.35% | $1.2B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Starling Oncology, Inc. | Nasdaq: STLN | Current | Services-Offices & Clinics of Doctors of Medicine | COM | 4,610,052 | 0 | 0.0% | 4.52% | $21M | +$3M | 0.33% | $324M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Avalyn Pharma Inc. | Nasdaq: AVLN | Current | Pharmaceutical Preparations | COM SHS | 731,000 | 0 | 0.0% | 1.65% | $21M | -$3M | 0.32% | $1.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Alamar Biosciences, Inc. | Nasdaq: ALMR | Current | Laboratory Analytical Instruments | COMMON STOCK | 600,000 | 0 | 0.0% | 0.86% | $20M | +$4M | 0.32% | $2.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: TYRA | Current | Pharmaceutical Preparations | COM | 732,392 | -284,608 | -28.0% | 1.06% | $16M | -$16M | 0.25% | $1.4B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Foghorn Therapeutics Inc. | Nasdaq: FHTX | Current | Pharmaceutical Preparations | COM | 4,394,367 | 0 | 0.0% | 7.33% | $16M | -$6M | 0.24% | $107M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Vogenx, Inc. | Nasdaq: VOGX | Current | Pharmaceutical Preparations | COM | 635,707 | +635,707 | New | 4.28% | $14M | +$14M | 0.22% | $190M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Embecta Corp. | Nasdaq: EMBC | Current | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 2,534,961 | 0 | 0.0% | 4.47% | $14M | +$6M | 0.22% | $351M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BBOT | Current | Pharmaceutical Preparations | COM NEW | 3,138,167 | -1,747,279 | -35.8% | 3.91% | $13M | -$24M | 0.20% | $149M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: NEO | Current | Services-Testing Laboratories | NOTE 0.250% 1/1 | +0.4% | $12M | +$0.0M | 0.19% | $2.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: DRUG | Current | Pharmaceutical Preparations | COM NEW | 236,295 | -46,705 | -16.5% | $12M | -$8M | 0.18% | $204M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: MNPR | Current | Pharmaceutical Preparations | COM NEW | 137,591 | -186,154 | -57.5% | 2.03% | $11M | -$19M | 0.17% | $476M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Adagene Inc. | Nasdaq: ADAG | Current | Pharmaceutical Preparations | ADS | 2,666,666 | 0 | 0.0% | $9M | -$3M | 0.13% | $135M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Hemab Therapeutics Holdings, Inc. | Nasdaq: COAG | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 275,000 | 0 | 0.0% | 0.59% | $8M | -$2M | 0.13% | $1.9B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ETRA | Current | Biological Products, (No Diagnostic Substances) | COM | 700,000 | +700,000 | New | 1.11% | $8M | +$8M | 0.12% | $561M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ANNX | Current | Pharmaceutical Preparations | COM | 583,913 | 0 | 0.0% | $2M | -$0.9M | 0.04% | $651M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ALEC | Current | Biological Products, (No Diagnostic Substances) | COM | 1,055,192 | 0 | 0.0% | 0.71% | $2M | -$0.2M | 0.03% | $342M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: EW | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 13,702 | 0 | 0.0% | <0.01% | $1M | -$0.1M | 0.02% | $59.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MIRM | Current | Pharmaceutical Preparations | COM | 6,027 | 0 | 0.0% | 0.01% | $0.5M | -$0.2M | 0.01% | $6.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: HUM | Current | Hospital & Medical Service Plans | COM | 917 | 0 | 0.0% | <0.01% | $0.3M | -$0.0M | 0.01% | $45.6B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| PMV Pharmaceuticals, Inc. | Nasdaq: PMVP | Current | Pharmaceutical Preparations | COM | 8,790 | 0 | 0.0% | 0.01% | $0.0M | +$0.0M | 0.00% | $99M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 |
| Nuvalent Inc | Exited | COM | 0 | -17,248,450 | -100.0% | -$2.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Merus N V | Exited | COM | 0 | -3,046,916 | -100.0% | -$287M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| NYSE: OSCR | Exited | Hospital & Medical Service Plans | CL A | 0 | -11,649,591 | -100.0% | -$250M | $8.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Exited | NOTE 0.500% 4/0 | -100.0% | -$131M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||||||||
| Indivior PLC | Exited | ORD | 0 | -3,393,063 | -100.0% | -$122M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: WAY | Exited | Services-Computer Integrated Systems Design | COM | 0 | -3,295,260 | -100.0% | -$121M | $5.2B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: KURA | Exited | Pharmaceutical Preparations | COM | 0 | -5,411,571 | -100.0% | -$106M | $675M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: BMY | Exited | Pharmaceutical Preparations | COM | 0 | -2,337,771 | -100.0% | -$105M | $119B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Catalyst Pharmaceuticals Inc | Exited | COM | 0 | -3,943,600 | -100.0% | -$98M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: MRK | Exited | Pharmaceutical Preparations | COM | 0 | -1,030,000 | -100.0% | -$86M | $327B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: LNTH | Exited | In Vitro & In Vivo Diagnostic Substances | COM | 0 | -752,999 | -100.0% | -$84M | $6.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: NBIX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -610,000 | -100.0% | -$80M | $15.8B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Day One Biopharmaceuticals Inc | Exited | COM | 0 | -3,723,131 | -100.0% | -$80M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: PFE | Exited | Pharmaceutical Preparations | COM | 0 | -3,040,000 | -100.0% | -$73M | $156B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: INSM | Exited | Pharmaceutical Preparations | COM PAR $.01 | 0 | -471,000 | -100.0% | -$68M | $31.7B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: SUPN | Exited | Pharmaceutical Preparations | COM | 0 | -1,648,895 | -100.0% | -$68M | $1.7B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Dynavax Technologies | Exited | COM NEW | 0 | -5,191,493 | -100.0% | -$67M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Enhabit Inc | Exited | COM | 0 | -4,747,746 | -100.0% | -$67M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Owens & Minor Inc New | ACCH | Exited | COM | 0 | -4,911,979 | -100.0% | -$64M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||||
| NYSE: BAX | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -1,923,100 | -100.0% | -$58M | $13.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: CDNA | Exited | Services-Medical Laboratories | COM | 0 | -1,997,618 | -100.0% | -$57M | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: CVS | Exited | Retail-Drug Stores and Proprietary Stores | COM | 0 | -874,800 | -100.0% | -$55M | $102B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: KYMR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -561,170 | -100.0% | -$47M | $10.2B | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Alphatec Holdings, Inc. | Nasdaq: ATEC | Exited | Surgical & Medical Instruments & Apparatus | NOTE 0.750% 8/0 | -100.0% | -$47M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: LKFT | Exited | Pharmaceutical Preparations | SPON ADR | 0 | -1,411,000 | -100.0% | -$39M | $2.2B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| NYSE: PHR | Exited | Services-Business Services, NEC | COM | 0 | -1,999,045 | -100.0% | -$34M | $737M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Chimerix Inc | Exited | COM | 0 | -3,771,342 | -100.0% | -$32M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: BCAX | Exited | Pharmaceutical Preparations | COM | 0 | -1,795,174 | -100.0% | -$31M | $605M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: SION | Exited | Pharmaceutical Preparations | COM | 0 | -680,916 | -100.0% | -$30M | $134M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: MRNA | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$29M | $80.7B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| InMode Ltd. | Nasdaq: INMD | Exited | Electromedical & Electrotherapeutic Apparatus | SHS | 0 | -1,578,708 | -100.0% | -$28M | $731M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| NYSE: VTR | Exited | Real Estate Investment Trusts | COM | 0 | -354,000 | -100.0% | -$27M | $46.0B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Immunocore Holdings plc | Nasdaq: IMCR | Exited | Biological Products, (No Diagnostic Substances) | NOTE 2.500% 2/0 | -100.0% | -$27M | $1.4B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | |||||
| NYSE: PACS | Exited | Services-Skilled Nursing Care Facilities | COM SHS | 0 | -663,851 | -100.0% | -$27M | $6.8B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Exited | Pharmaceutical Preparations | COM NEW | 0 | -710,626 | -100.0% | -$23M | $9.3B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: CGON | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -850,695 | -100.0% | -$21M | $7.3B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: BNTX | Exited | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 0 | -174,500 | -100.0% | -$21M | $20.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ALNY | Exited | Pharmaceutical Preparations | COM | 0 | -67,935 | -100.0% | -$20M | $19.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Establishment Labs Hldgs Inc | Exited | COM | -100.0% | -$20M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||||||
| Liquidia Corp | Nasdaq: LQDA | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,616,778 | -100.0% | -$20M | $5.1B | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: SEPN | Exited | Pharmaceutical Preparations | COM | 0 | -861,814 | -100.0% | -$20M | $1.9B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: CMPX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -3,606,000 | -100.0% | -$19M | $122M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: EWTX | Exited | Pharmaceutical Preparations | COM | 0 | -765,694 | -100.0% | -$19M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||||
| Nasdaq: MREO | Exited | Pharmaceutical Preparations | SPON ADS | 0 | -6,710,429 | -100.0% | -$18M | $44M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Xeris Biopharma Holdings, Inc. | Nasdaq: XERS | Exited | Pharmaceutical Preparations | COM | 0 | -22,574 | -100.0% | -$18M | $3.0B | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | |||
| Kyverna Therapeutics, Inc. | Nasdaq: KYTX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -2,000,000 | -100.0% | -$18M | $276M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||
| Nasdaq: BEAM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -877,809 | -100.0% | -$17M | $2.2B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: RXRX | Exited | Biological Products, (No Diagnostic Substances) | CL A | 0 | -2,315,000 | -100.0% | -$16M | $1.7B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: NVCR | Exited | Surgical & Medical Instruments & Apparatus | ORD SHS | 0 | -825,119 | -100.0% | -$15M | $1.2B | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Concentra Group Holdings Parent, Inc. | NYSE: CON | Exited | Services-Specialty Outpatient Facilities, NEC | COMMON STOCK | 0 | -650,000 | -100.0% | -$14M | $5.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Metsera Inc | Exited | COM | 0 | -500,000 | -100.0% | -$14M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||
| Autolus Therapeutics plc | Nasdaq: AUTL | Exited | Biological Products, (No Diagnostic Substances) | SPON ADS | 0 | -3,639,000 | -100.0% | -$13M | $261M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: CRMD | Exited | Pharmaceutical Preparations | COM | 0 | -1,107,944 | -100.0% | -$13M | $404M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| SpyGlass Pharma, Inc. | Nasdaq: SGP | Exited | Surgical & Medical Instruments & Apparatus | COM SHS | 0 | -550,000 | -100.0% | -$12M | $1.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | |||
| Nasdaq: TSHA | Exited | Biological Products, (No Diagnostic Substances) | COM SHS | 0 | -2,722,165 | -100.0% | -$12M | $1.2B | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: RXST | Exited | Ophthalmic Goods | COM | 0 | -888,950 | -100.0% | -$12M | $193M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: OPK | Exited | Pharmaceutical Preparations | COM | 0 | -6,906,362 | -100.0% | -$11M | $1.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| INTEGRA LIFESCIENCES HOLDINGS CORP | Nasdaq: IART | Exited | Surgical & Medical Instruments & Apparatus | COM NEW | 0 | -794,865 | -100.0% | -$11M | $1.1B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: DCTH | Exited | Surgical & Medical Instruments & Apparatus | COM NEW | 0 | -812,561 | -100.0% | -$11M | $669M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Medline Inc. | Nasdaq: MDLN | Exited | Surgical & Medical Instruments & Apparatus | COM CL A | 0 | -260,000 | -100.0% | -$11M | $49.8B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||
| Third Harmonic Bio Inc | Exited | COM | 0 | -1,019,700 | -100.0% | -$10M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| GH Research PLC | Nasdaq: GHRS | Exited | Pharmaceutical Preparations | ORDINARY SHARES | 0 | -925,000 | -100.0% | -$10M | $1.3B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | |||
| Mobia Medical, Inc. | Nasdaq: MOBI | Exited | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 0 | -670,752 | -100.0% | -$9M | $395M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | |||
| Nasdaq: OMDA | Exited | Services-Health Services | COM | 0 | -553,107 | -100.0% | -$9M | $775M | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| CalciMedica, Inc. | Nasdaq: CALC | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,300,000 | -100.0% | -$9M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: DYN | Exited | Pharmaceutical Preparations | COM | 0 | -812,408 | -100.0% | -$8M | $3.0B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Prelude Therapeutics Inc | Nasdaq: PRLD | Exited | Pharmaceutical Preparations | COM | 0 | -3,766,120 | -100.0% | -$8M | $261M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: PCVX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -225,000 | -100.0% | -$7M | $9.2B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| DocGo Inc. | Nasdaq: DCGO | Exited | Transportation Services | COM | 0 | -4,622,708 | -100.0% | -$6M | $17M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Simulations Plus Inc | Exited | COM | 0 | -354,089 | -100.0% | -$6M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| SHOULDER INNOVATIONS, INC. | NYSE: SI | Exited | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 0 | -482,572 | -100.0% | -$6M | $425M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Perspective Therapeutics, Inc. | NYSE: CATX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -2,829,413 | -100.0% | -$6M | $95M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: VCYT | Exited | Services-Medical Laboratories | COM | 0 | -101,000 | -100.0% | -$6M | $2.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: FATE | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -3,555,871 | -100.0% | -$6M | $123M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: NPCE | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -500,000 | -100.0% | -$6M | $280M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: CGEM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -386,169 | -100.0% | -$5M | $589M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: NKTX | Exited | Pharmaceutical Preparations | COM | 0 | -2,155,000 | -100.0% | -$5M | $80M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: CRVS | Exited | Pharmaceutical Preparations | COM | 0 | -1,000,000 | -100.0% | -$5M | $844M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Neurogene Inc. | Nasdaq: NGNE | Exited | Pharmaceutical Preparations | COM | 0 | -446,880 | -100.0% | -$5M | $475M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: LUNG | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -1,890,000 | -100.0% | -$5M | $119M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: JBIO | Exited | Pharmaceutical Preparations | COM NEW | 0 | -531,163 | -100.0% | -$5M | $1.0B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| NYSE: PBH | Exited | Pharmaceutical Preparations | COM | 0 | -69,669 | -100.0% | -$4M | $2.4B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: VEEV | Exited | Services-Prepackaged Software | CL A COM | 0 | -17,711 | -100.0% | -$4M | $42.6B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Hillevax Inc | Exited | COM | 0 | -1,882,654 | -100.0% | -$4M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: UFPT | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -18,660 | -100.0% | -$4M | $2.3B | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: RDNT | Exited | Services-Medical Laboratories | COM | 0 | -49,951 | -100.0% | -$4M | $5.5B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Varex Imaging Corp | Nasdaq: VREX | Exited | Electronic Components, NEC | COM | 0 | -285,207 | -100.0% | -$4M | $770M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: MMSI | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -41,846 | -100.0% | -$3M | $5.1B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: PRME | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -896,960 | -100.0% | -$3M | $856M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: LH | Exited | Services-Medical Laboratories | COM SHS | 0 | -13,825 | -100.0% | -$3M | $30.0B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Enovis CORP | NYSE: ENOV | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 0 | -127,270 | -100.0% | -$3M | $1.5B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | |||
| NYSE: HAE | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -69,089 | -100.0% | -$3M | $5.5B | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: HTFL | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -100,000 | -100.0% | -$3M | $3.9B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Singular Genomics Systems In | Exited | COM NEW | 0 | -166,162 | -100.0% | -$3M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| NYSE: DGX | Exited | Services-Medical Laboratories | COM | 0 | -18,392 | -100.0% | -$3M | $28.5B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: KVUE | Exited | COM | 0 | -193,853 | -100.0% | -$3M | $37.1B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||||
| TransMedics Group, Inc. | Nasdaq: TMDX | Exited | Electromedical & Electrotherapeutic Apparatus | COM | 0 | -25,492 | -100.0% | -$3M | $3.3B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: PODD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -10,616 | -100.0% | -$3M | $9.5B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| REVVITY, INC. | NYSE: RVTY | Exited | Laboratory Analytical Instruments | COM | 0 | -33,541 | -100.0% | -$3M | $16.9B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Biolife Solutions Inc | Exited | COM NEW | 0 | -120,211 | -100.0% | -$3M | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Petco Health & Wellness Company, Inc. | Nasdaq: WOOF | Exited | Retail-Retail Stores, NEC | COM | 0 | -936,309 | -100.0% | -$3M | $710M | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | |||
| STAAR SURGICAL CO | Nasdaq: STAA | Exited | Ophthalmic Goods | COM PAR $0.01 | 0 | -96,989 | -100.0% | -$3M | $1.3B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: KIDS | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -144,220 | -100.0% | -$3M | $849M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: MLAB | Exited | Industrial Instruments For Measurement, Display, and Control | COM | 0 | -19,664 | -100.0% | -$3M | $750M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: CI | Exited | Hospital & Medical Service Plans | COM | 0 | -9,203 | -100.0% | -$3M | $71.4B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| TRUPANION, INC. | Nasdaq: TRUP | Exited | Hospital & Medical Service Plans | COM | 0 | -66,438 | -100.0% | -$2M | $1.6B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| RESMED INC | NYSE: RMD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -10,104 | -100.0% | -$2M | $33.3B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: ISRG | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM NEW | 0 | -5,438 | -100.0% | -$2M | $138B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| NYSE: AIN | Exited | Broadwoven Fabric Mills, Man Made Fiber & Silk | CL A | 0 | -26,848 | -100.0% | -$2M | $1.8B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: DVA | Exited | Services-Misc Health & Allied Services, NEC | COM | 0 | -20,909 | -100.0% | -$2M | $9.8B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: WAT | Exited | Laboratory Analytical Instruments | COM | 0 | -7,885 | -100.0% | -$2M | $86.6B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| NYSE: DOCS | Exited | Services-Computer Programming Services | CL A | 0 | -51,942 | -100.0% | -$2M | $5.3B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: DXCM | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -32,943 | -100.0% | -$2M | $29.9B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: IRTC | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -12,099 | -100.0% | -$2M | $3.2B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: CNMD | Exited | Electromedical & Electrotherapeutic Apparatus | COM | 0 | -52,555 | -100.0% | -$2M | $1.4B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: FTRE | Exited | Services-Medical Laboratories | COMMON STOCK | 0 | -105,470 | -100.0% | -$2M | $1.9B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Masimo Corp | Exited | COM | 0 | -16,147 | -100.0% | -$2M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| LEMAITRE VASCULAR INC | Nasdaq: LMAT | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -25,815 | -100.0% | -$2M | $1.7B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | |||
| 10x Genomics, Inc. | Nasdaq: TXG | Exited | Laboratory Analytical Instruments | CL A COM | 0 | -126,574 | -100.0% | -$2M | $7.5B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: ATRC | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -52,076 | -100.0% | -$2M | $2.8B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: NVDA | Exited | Semiconductors & Related Devices | COM | 0 | -16,318 | -100.0% | -$2M | $3.03T | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| CENTRAL GARDEN & PET CO | Nasdaq: CENT | Exited | Wholesale-Miscellaneous Nondurable Goods | COM | 0 | -53,827 | -100.0% | -$2M | $2.9B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Advanced Flower Capital Inc. | Nasdaq: AFCG | Exited | COM | 0 | -191,162 | -100.0% | -$2M | $74M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Avanos Med Inc | Exited | COM | 0 | -167,061 | -100.0% | -$2M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: CRVL | Exited | Insurance Agents, Brokers & Service | COM | 0 | -27,629 | -100.0% | -$2M | $4.4B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Cardinal Health | NYSE: CAH | Exited | Wholesale-Drugs, Proprietaries & Druggists' Sundries | COM | 0 | -8,985 | -100.0% | -$2M | $62.9B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| GoodRx Holdings, Inc. | Nasdaq: GDRX | Exited | Services-Computer Processing & Data Preparation | COM CL A | 0 | -660,133 | -100.0% | -$2M | $1.0B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: OTTR | Exited | Electric Services | COM | 0 | -22,452 | -100.0% | -$2M | $3.3B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: SGRY | Exited | Services-General Medical & Surgical Hospitals, NEC | COM | 0 | -112,623 | -100.0% | -$2M | $3.5B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ALGN | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 0 | -11,000 | -100.0% | -$2M | $11.3B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ADUS | Exited | Services-Home Health Care Services | COM | 0 | -15,871 | -100.0% | -$2M | $2.3B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: WSO | Exited | Wholesale-Hardware & Plumbing & Heating Equipment & Supplies | COM | 0 | -3,401 | -100.0% | -$2M | $12.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: DFIN | Exited | Services-Miscellaneous Business Services | COM | 0 | -24,968 | -100.0% | -$2M | $1.6B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: UAA | Exited | Apparel & Other Finishd Prods of Fabrics & Similar Matl | CL A | 0 | -184,457 | -100.0% | -$2M | $1.9B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: LOW | Exited | Retail-Lumber & Other Building Materials Dealers | COM | 0 | -5,913 | -100.0% | -$2M | $124B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: FBNC | Exited | State Commercial Banks | COM | 0 | -38,451 | -100.0% | -$2M | $2.6B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: OXM | Exited | Men's & Boys' Furnishgs, Work Clothg, & Allied Garments | COM | 0 | -18,184 | -100.0% | -$2M | $382M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Premier Inc | Exited | CL A | 0 | -78,878 | -100.0% | -$2M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| NYSE: IEX | Exited | Pumps & Pumping Equipment | COM | 0 | -7,106 | -100.0% | -$2M | $16.7B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: BDX | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -6,312 | -100.0% | -$2M | $58.0B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Privia Health Group, Inc. | Nasdaq: PRVA | Exited | Services-Health Services | COM | 0 | -79,941 | -100.0% | -$1M | $3.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Byrna Technologies Inc. | Nasdaq: BYRN | Exited | Miscellaneous Electrical Machinery, Equipment & Supplies | COM NEW | 0 | -85,037 | -100.0% | -$1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ANDE | Exited | Wholesale-Farm Product Raw Materials | COM | 0 | -28,632 | -100.0% | -$1M | $1.6B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: MMS | Exited | Services-Business Services, NEC | COM | 0 | -15,377 | -100.0% | -$1M | $3.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ODFL | Exited | Trucking (No Local) | COM | 0 | -7,199 | -100.0% | -$1M | $35.8B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Weave Communications, Inc. | Exited | COM | 0 | -108,555 | -100.0% | -$1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Exact Sciences Corp | Exited | COM | 0 | -20,341 | -100.0% | -$1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: IDXX | Exited | In Vitro & In Vivo Diagnostic Substances | COM | 0 | -2,643 | -100.0% | -$1M | $53.3B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Ventyx Biosciences Inc | Exited | COM | 0 | -534,737 | -100.0% | -$1M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: TWST | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -23,827 | -100.0% | -$0.9M | $7.6B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: SHC | Exited | Services-Misc Health & Allied Services, NEC | COM | 0 | -45,242 | -100.0% | -$0.5M | $4.6B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Biomx Inc | Exited | COM NEW | 0 | -131,272 | -100.0% | -$0.5M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: TMO | Exited | Measuring & Controlling Devices, NEC | COM | 0 | -916 | -100.0% | -$0.4M | $248B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Veradermics, Inc | NYSE: MANE | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -5,000 | -100.0% | -$0.3M | $5.2B | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| NATIONAL HEALTHCARE CORP | NYSE: NHC | Exited | Services-Skilled Nursing Care Facilities | COM | 0 | -2,926 | -100.0% | -$0.3M | $3.0B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | |||
| NYSE: UHS | Exited | Services-General Medical & Surgical Hospitals, NEC | CL B | 0 | -1,597 | -100.0% | -$0.3M | $10.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Amedisys Inc | Exited | COM | 0 | -2,744 | -100.0% | -$0.3M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| NYSE: IQV | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -1,623 | -100.0% | -$0.3M | $41.3B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| MIMEDX GROUP, INC. | Nasdaq: MDXG | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -39,351 | -100.0% | -$0.2M | $454M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: MEDP | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -736 | -100.0% | -$0.2M | $17.7B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: GIS | Exited | Grain Mill Products | COM | 0 | -3,455 | -100.0% | -$0.2M | $18.4B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: AMPH | Exited | Pharmaceutical Preparations | COM | 0 | -9,579 | -100.0% | -$0.2M | $1.2B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: JOE | Exited | Land Subdividers & Developers (No Cemeteries) | COM | 0 | -4,473 | -100.0% | -$0.2M | $3.7B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: DXC | Exited | Services-Computer Processing & Data Preparation | COM | 0 | -11,883 | -100.0% | -$0.2M | $2.1B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Xponential Fitness, Inc. | NYSE: XPOF | Exited | Services-Miscellaneous Amusement & Recreation | COM CL A | 0 | -23,097 | -100.0% | -$0.2M | $197M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Farmland Partners Inc. | NYSE: FPI | Exited | Real Estate Investment Trusts | COM | 0 | -16,863 | -100.0% | -$0.2M | $386M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: HNRG | Exited | Electric Services | COM | 0 | -13,713 | -100.0% | -$0.2M | $468M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| RING ENERGY, INC. | NYSE: REI | Exited | Crude Petroleum & Natural Gas | COM | 0 | -127,376 | -100.0% | -$0.1M | $276M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Enlink Midstream LLC | Exited | Fund | COM UNIT REP LTD | 0 | -10,257 | -100.0% | -$0.1M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||||
| Nasdaq: HNST | Exited | Retail-Catalog & Mail-Order Houses | COM | 0 | -20,171 | -100.0% | -$0.1M | $489M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| NYSE: EBS | Exited | Pharmaceutical Preparations | COM | 0 | -14,058 | -100.0% | -$0.1M | $265M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| NYSE: NUVB | Exited | Pharmaceutical Preparations | *W EXP 02/10/202 | 0 | -212,114 | -100.0% | -$0.1M | $1.3B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: HTLD | Exited | Trucking (No Local) | COM | 0 | -11,547 | -100.0% | -$0.1M | $780M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Mfa Finl Inc | Exited | COM | 0 | -10,935 | -100.0% | -$0.1M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: BLZE | Exited | Services-Prepackaged Software | COM CL A | 0 | -21,475 | -100.0% | -$0.1M | $459M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: VIR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -15,728 | -100.0% | -$0.1M | $1.7B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| MediaAlpha, Inc. | NYSE: MAX | Exited | Services-Business Services, NEC | CL A | 0 | -10,795 | -100.0% | -$0.1M | $804M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| UNISYS CORP | NYSE: UIS | Exited | Services-Computer Integrated Systems Design | COM NEW | 0 | -15,627 | -100.0% | -$0.1M | $198M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| NYSE: BFLY | Exited | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | *W EXP 02/12/202 | 0 | -744,968 | -100.0% | -$0.1M | $1.6B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: EGY | Exited | Crude Petroleum & Natural Gas | COM NEW | 0 | -20,897 | -100.0% | -$0.1M | $519M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: MNKD | Exited | Pharmaceutical Preparations | COM NEW | 0 | -17,380 | -100.0% | -$0.1M | $1.3B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Hanesbrands Inc | Exited | COM | 0 | -10,619 | -100.0% | -$0.1M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| DIVERSIFIED HEALTHCARE TRUST | Nasdaq: DHC | Exited | Real Estate Investment Trusts | COM SH BEN INT | 0 | -33,892 | -100.0% | -$0.1M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: GNW | Exited | Life Insurance | COM SHS | 0 | -11,307 | -100.0% | -$0.1M | $2.8B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| NYSE: ECVT | Exited | Chemicals & Allied Products | COM | 0 | -10,317 | -100.0% | -$0.1M | $1.0B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| CERUS CORP | Nasdaq: CERS | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -50,305 | -100.0% | -$0.1M | $384M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Equity Comwlth | Exited | COM SH BEN INT | 0 | -43,258 | -100.0% | -$0.1M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| NYSE: ACCO | Exited | Blankbooks, Looseleaf Binders & Bookbindg & Relatd Work | COM | 0 | -14,557 | -100.0% | -$0.1M | $506M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| ORASURE TECHNOLOGIES INC | Nasdaq: OSUR | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -20,898 | -100.0% | -$0.1M | $249M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| NYSE: NUS | Exited | Wholesale-Drugs, Proprietaries & Druggists' Sundries | CL A | 0 | -10,194 | -100.0% | -$0.1M | $184M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| BRC Inc | Exited | COM CL A | 0 | -15,029 | -100.0% | -$0.0M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Quantum Si Inc | Exited | *W EXP 06/10/202 | 0 | -333,333 | -100.0% | -$0.0M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Surrozen, Inc./DE | Nasdaq: SRZN | Exited | Biological Products, (No Diagnostic Substances) | *W EXP 08/01/203 | 0 | -166,666 | -100.0% | -$0.0M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: MYGN | Exited | In Vitro & In Vivo Diagnostic Substances | COM | 0 | -505 | -100.0% | -$0.0M | $531M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 |
Alexander AshavskyManaging Director, Data Science and Engineering · Present
Anne DaubPartner · Present
Brian ChowManaging Director · Present
Daniel GlassManaging Director, Global Market Research · Present
David GreenwaldManaging Director · Present
Deerfield IntelligenceManaging Director, Data Analytics · Present
Jackson HarveyPrincipal · Present
Jared AndermanManaging Director, Data Analytics · Present
Jason FullerPartner · Present
Jim FlynnManaging Partner · Present
Jonathan IslerPartner and Chief Financial Officer, Funds · Present
Karen HeidelbergerPartner and Chief Partnerships Officer · Present
Katherine LazarPrincipal, Investment Strategy · Present
Leslie HenshawPartner · Present
Michael BergenManaging Director · Present
Moses AdubiPrincipal · Present
Nehan ChatoorPrincipal · Present
Nicholas BishopPartner · Present
Oleg LaptenkoPrincipal Scientist, Preclinical Pharmacology · Present
Stephen AnastosManaging Director · Present
Sumner AndersonPartner · Present
Talia AskowitzPrincipal · Present
Terence Fox-KarnalPartner and Head Equity Linked and Credit Trader · Present
Timothy LeahyPartner · Present